290 episodes

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

The Bio Report The Bio Report

    • Investing

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

    Thoughts on the State of the Antimicrobial Arsenal

    Thoughts on the State of the Antimicrobial Arsenal

    The latest reports on the coronavirus outbreak put the number of infections at nearly 75,000 and deaths at more than 2,100. Against the backdrop of the outbreak, we spoke to Evan Loh, chairman of the Antimicrobials Working Group and CEO of Paratek Pharmaceuticals, about the global changes that are fueling the threat of infectious disease outbreaks, the state of the antimicrobial arsenal, and what needs to be done to spur the development of new agents to combat the rise deadly bugs.

    • 28 min
    A MedTech Company That Thinks Like a Biopharma

    A MedTech Company That Thinks Like a Biopharma

    Orchestra BioMed may play at the intersection of drugs and devices, but’s its business strategy is clearly drawn from the biopharmaceutical industry. The company develops its pipeline and then leverages strategic alliances with global partners who can best commercialize its products and maximize their potential. We spoke to David Hochman, CEO of Orchestra BioMed, about the company’s therapeutic devices, the large market opportunities it is targeting, and how it seeks to rewrite the way medtech companies think about partnering.

    • 33 min
    Tapping the Potential of Psychedelics to Treat Psychiatric Conditions

    Tapping the Potential of Psychedelics to Treat Psychiatric Conditions

    Psychedelics have long been viewed as having potential to treat a range of mental health disorders including depression, addiction, PTSD, and ADHD. Government policies, though, have long impeded studies of their benefits. Mind Medicine is developing a pipeline of therapies based on psychedelics in the hopes of developing needed medicines for psychiatric conditions. Its lead experimental therapy is an ibogaine-derived molecule for the treatment of opioid addiction. We spoke to Steve Hurst, founder and CEO of MindMed, about the potential for psychedelic-based medicines, what’s known about them to date, and the challenges of working with these substances.

    • 38 min
    Quantifying Neurodegeneration with Precision

    Quantifying Neurodegeneration with Precision

    The difficulty in diagnosing Alzheimer’s disease and identifying it at its earliest stages when interventions offer the best opportunity for success, is one of the critical challenges in addressing the neurodegenerative condition. CorTechs Labs has developed quantitative analysis software that allows physicians to analyze brain images to diagnose and monitor patients with the diseases. We spoke to Chris Airriess, CEO of CorTechs, about the difficulty in diagnosing Alzheimer’s disease today, how its technology works, and its efforts to marry its software to genetic data as a way to identify and monitor people who may be at risk of developing the disease.

    • 22 min
    Orasis Developing Eye Drops as Alternative to Reading Glasses

    Orasis Developing Eye Drops as Alternative to Reading Glasses

    As people age, the ability of their eyes to focus on objects near to them weakens. The condition, known as presbyopia, affects more than 1.8 billion people worldwide. Though reading glasses provide a solution to the problem, Orasis Pharmaceuticals is developing a corrective eyedrop it says will provide an alternative. We spoke to Elad Kedar, CEO of Orasis, about aging eyes, its experimental eye drop intended to allow people to free themselves from a dependency on reading glasses, and how it works.

    • 22 min
    Reversing Disease Signals

    Reversing Disease Signals

    Ben Zeskind likens Immuneering’s platform technology to noise-cancelling headphones. Infact, the company’s use of the term “Disease Cancelling Technology” speaks directly to that. The approach, he says, allows the company to build a pipeline of drug candidate that address aspects of disease that have eluded tradition drug development approaches. We spoke Zeskind, CEO of Immuneering, about the company’s evolution from its roots in bioinformatics, its movement into drug development, and how its proprietary platform technology works.

    • 31 min

Top Podcasts In Investing

Listeners Also Subscribed To